Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo

An oxidative stress based apoptosis, physicochemical and neurological study profile

Gheyath K. Nasrallah, Rola Salem, Sahar Da'as, Ola Loay Ahmad Al-Jamal, Mark Scott, Ibrahim Mustafa

Research output: Contribution to journalArticle

Abstract

Objectives: Clinically approved iron chelators are effective in decreasing significant transfusional iron accumulation. Starch-Deferoxamine (S-DFO), a novel high molecular weight iron chelator, was produced to increase binding capacity to iron and reduce toxicity. Although its efficacy was established in one small cohort clinical trial, its potential adverse effect was not adequately addressed. Methods: We utilized zebrafish model to assess S-DFO toxicity using following assays: mortality, teratogenicity, hatching rate, tail flicking, Acridine Orange staining for apoptosis detection, o-dianisidine staining for hemoglobin synthesis, and the level of Hsp70 as a general stress indicator. Embryos were exposed to different concentrations of S-DFO, Zinc Oxide nanoparticle (ZnO) (positive control), along with untreated control (UC). Results: S-DFO showed no significant mortality nor deformities at all tested concentrations (0.0–1000 μM). Thus, the LC50 is expected to >1000 μM. 100 μM S-DFO treatment did not affect embryo development (as judged by hatching rate); neuromuscular activity (as judged by tail flicking); and hemoglobin synthesis. Neither apoptosis, nor increase in Hsp70 level was noticed upon S-DFO treatment. Conclusion: Our assays demonstrate that S-DFO does not induce cellular or biochemical stress and has no adverse effect on organ development of zebrafish embryos, suggesting its safe use as an iron chelator.

Original languageEnglish
Pages (from-to)29-38
Number of pages10
JournalNeurotoxicology and Teratology
Volume72
DOIs
Publication statusPublished - 1 Mar 2019

Fingerprint

Zinc Oxide
Deferoxamine
Oxidative stress
Zebrafish
Chelating Agents
Biocompatibility
Starch
Nanoparticles
Toxicity
Oxidative Stress
Embryonic Structures
Iron
Apoptosis
Embryonic Development
Tail
Assays
Hemoglobins
Dianisidine
Staining and Labeling
Acridine Orange

Keywords

  • Iron chelation
  • S-DFO
  • Toxicity
  • Zebrafish
  • ZnO

ASJC Scopus subject areas

  • Toxicology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience

Cite this

Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo : An oxidative stress based apoptosis, physicochemical and neurological study profile. / Nasrallah, Gheyath K.; Salem, Rola; Da'as, Sahar; Al-Jamal, Ola Loay Ahmad; Scott, Mark; Mustafa, Ibrahim.

In: Neurotoxicology and Teratology, Vol. 72, 01.03.2019, p. 29-38.

Research output: Contribution to journalArticle

@article{65e498e1380547298c5d1f0ddb205e65,
title = "Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo: An oxidative stress based apoptosis, physicochemical and neurological study profile",
abstract = "Objectives: Clinically approved iron chelators are effective in decreasing significant transfusional iron accumulation. Starch-Deferoxamine (S-DFO), a novel high molecular weight iron chelator, was produced to increase binding capacity to iron and reduce toxicity. Although its efficacy was established in one small cohort clinical trial, its potential adverse effect was not adequately addressed. Methods: We utilized zebrafish model to assess S-DFO toxicity using following assays: mortality, teratogenicity, hatching rate, tail flicking, Acridine Orange staining for apoptosis detection, o-dianisidine staining for hemoglobin synthesis, and the level of Hsp70 as a general stress indicator. Embryos were exposed to different concentrations of S-DFO, Zinc Oxide nanoparticle (ZnO) (positive control), along with untreated control (UC). Results: S-DFO showed no significant mortality nor deformities at all tested concentrations (0.0–1000 μM). Thus, the LC50 is expected to >1000 μM. 100 μM S-DFO treatment did not affect embryo development (as judged by hatching rate); neuromuscular activity (as judged by tail flicking); and hemoglobin synthesis. Neither apoptosis, nor increase in Hsp70 level was noticed upon S-DFO treatment. Conclusion: Our assays demonstrate that S-DFO does not induce cellular or biochemical stress and has no adverse effect on organ development of zebrafish embryos, suggesting its safe use as an iron chelator.",
keywords = "Iron chelation, S-DFO, Toxicity, Zebrafish, ZnO",
author = "Nasrallah, {Gheyath K.} and Rola Salem and Sahar Da'as and Al-Jamal, {Ola Loay Ahmad} and Mark Scott and Ibrahim Mustafa",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.ntt.2019.01.004",
language = "English",
volume = "72",
pages = "29--38",
journal = "Neurotoxicology and Teratology",
issn = "0892-0362",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo

T2 - An oxidative stress based apoptosis, physicochemical and neurological study profile

AU - Nasrallah, Gheyath K.

AU - Salem, Rola

AU - Da'as, Sahar

AU - Al-Jamal, Ola Loay Ahmad

AU - Scott, Mark

AU - Mustafa, Ibrahim

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Objectives: Clinically approved iron chelators are effective in decreasing significant transfusional iron accumulation. Starch-Deferoxamine (S-DFO), a novel high molecular weight iron chelator, was produced to increase binding capacity to iron and reduce toxicity. Although its efficacy was established in one small cohort clinical trial, its potential adverse effect was not adequately addressed. Methods: We utilized zebrafish model to assess S-DFO toxicity using following assays: mortality, teratogenicity, hatching rate, tail flicking, Acridine Orange staining for apoptosis detection, o-dianisidine staining for hemoglobin synthesis, and the level of Hsp70 as a general stress indicator. Embryos were exposed to different concentrations of S-DFO, Zinc Oxide nanoparticle (ZnO) (positive control), along with untreated control (UC). Results: S-DFO showed no significant mortality nor deformities at all tested concentrations (0.0–1000 μM). Thus, the LC50 is expected to >1000 μM. 100 μM S-DFO treatment did not affect embryo development (as judged by hatching rate); neuromuscular activity (as judged by tail flicking); and hemoglobin synthesis. Neither apoptosis, nor increase in Hsp70 level was noticed upon S-DFO treatment. Conclusion: Our assays demonstrate that S-DFO does not induce cellular or biochemical stress and has no adverse effect on organ development of zebrafish embryos, suggesting its safe use as an iron chelator.

AB - Objectives: Clinically approved iron chelators are effective in decreasing significant transfusional iron accumulation. Starch-Deferoxamine (S-DFO), a novel high molecular weight iron chelator, was produced to increase binding capacity to iron and reduce toxicity. Although its efficacy was established in one small cohort clinical trial, its potential adverse effect was not adequately addressed. Methods: We utilized zebrafish model to assess S-DFO toxicity using following assays: mortality, teratogenicity, hatching rate, tail flicking, Acridine Orange staining for apoptosis detection, o-dianisidine staining for hemoglobin synthesis, and the level of Hsp70 as a general stress indicator. Embryos were exposed to different concentrations of S-DFO, Zinc Oxide nanoparticle (ZnO) (positive control), along with untreated control (UC). Results: S-DFO showed no significant mortality nor deformities at all tested concentrations (0.0–1000 μM). Thus, the LC50 is expected to >1000 μM. 100 μM S-DFO treatment did not affect embryo development (as judged by hatching rate); neuromuscular activity (as judged by tail flicking); and hemoglobin synthesis. Neither apoptosis, nor increase in Hsp70 level was noticed upon S-DFO treatment. Conclusion: Our assays demonstrate that S-DFO does not induce cellular or biochemical stress and has no adverse effect on organ development of zebrafish embryos, suggesting its safe use as an iron chelator.

KW - Iron chelation

KW - S-DFO

KW - Toxicity

KW - Zebrafish

KW - ZnO

UR - http://www.scopus.com/inward/record.url?scp=85061388855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061388855&partnerID=8YFLogxK

U2 - 10.1016/j.ntt.2019.01.004

DO - 10.1016/j.ntt.2019.01.004

M3 - Article

VL - 72

SP - 29

EP - 38

JO - Neurotoxicology and Teratology

JF - Neurotoxicology and Teratology

SN - 0892-0362

ER -